WHO ICTRP trial
Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal…
JPRN-UMIN000018878 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000018878 |
|---|---|
| Public title | Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis |
| Scientific title | Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis - clinical study for pancreatic cancer with peritoneal metastasis |
| Primary sponsor | Study group of pancreatic cancer with peritoneal metastasis |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | The patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy. |
| Interventions | Gemcitabine (800-1000mg/m2, weekly for 3 weks with 1wk rest) and nab-paclitaxel(100-125mg/m2, weekly for 3 weks with 1wk rest) plus intraperitoneal paclitaxel administration (15-20mg/m2, weekly for 3 weks with 1wk rest) Regimen will be… |
| Registration date | Jan 9, 2015 |
| Target size | 48 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: